Kowsari Kavin, Lu Lynn, Persak Steven C, Hu Guangli, Forrest William, Berger Robert, Givand Jeffrey C, Babaee Sahab
Device Development and Technology, Merck Research Laboratories, Merck & Co. Inc., Rahway, NJ 07065, USA.
Device Development and Technology, Merck Research Laboratories, Merck & Co. Inc., Rahway, NJ 07065, USA.
J Pharm Sci. 2024 Dec;113(12):3525-3537. doi: 10.1016/j.xphs.2024.09.026. Epub 2024 Oct 5.
Administration of high-concentrated suspension formulations (i.e., solid particles dispersed in a liquid vehicle) can be limited due to their greater propensity for needle occlusion. The physical interaction between the solid phase (i.e., particles), the vehicle (i.e., flow field), and injection devices could result in the formation of particle bridging or filtering, posing a major risk in dose delivery accuracy and injectability. Here, given the limited understanding on how clogging initiates in syringe and needle delivery systems, we report an experimental approach to fully characterize the transient injection behavior of suspensions. In particular, we first established a custom fluorescence tagging and imaging technique with integrated force sensor to enable visual observation of local particle concentrations and plunger force monitoring throughout injection. Then, we investigated the effects of key formulation properties and device parameters including particle concentration and morphology, carrier viscosity, injection rate, needle and syringe sizes, and tissue backpressure on the incidence of suspension particle jamming and needle clogging. We performed systematic benchmark studies demonstrating that increasing needle inner diameter (ID) and particle density considerably reduced clogging risk, while increasing vehicle viscosity, particle size, and tissue backpressure significantly increased clogging. The experimental framework presented is amenable to quantifying clogging risk in drug-loaded particle suspensions and provides a guideline to make informed decisions on the tradeoffs between creating particles for pharmaceutical impact and feasibility of injection delivery.
高浓度混悬液制剂(即固体颗粒分散在液体载体中)的给药可能会受到限制,因为它们更容易造成针头堵塞。固相(即颗粒)、载体(即流场)和注射装置之间的物理相互作用可能导致颗粒桥连或过滤的形成,这对剂量递送准确性和可注射性构成重大风险。在此,鉴于对注射器和针头递送系统中堵塞如何起始的了解有限,我们报告一种实验方法来全面表征混悬液的瞬态注射行为。具体而言,我们首先建立了一种带有集成力传感器的定制荧光标记和成像技术,以便在整个注射过程中直观观察局部颗粒浓度并监测柱塞力。然后,我们研究了关键制剂性质和装置参数的影响,包括颗粒浓度和形态、载体粘度、注射速率、针头和注射器尺寸以及组织背压对混悬液颗粒堵塞和针头堵塞发生率的影响。我们进行了系统的基准研究,结果表明增加针头内径(ID)和颗粒密度可显著降低堵塞风险,而增加载体粘度、颗粒尺寸和组织背压则会显著增加堵塞。所提出的实验框架适用于量化载药颗粒混悬液中的堵塞风险,并为在制备具有药物作用的颗粒与注射递送可行性之间进行权衡时做出明智决策提供指导。